Status:
ACTIVE_NOT_RECRUITING
Serum Prevalence of SARS-Cov-2 Antibodies in Pre-pandemic Blood Samples (SPARE)
Lead Sponsor:
IRCCS San Raffaele Roma
Collaborating Sponsors:
Department of Transfusion Medicine Venice Area
Istituto per lo Studio, la Prevenzione e la Rete Oncologica
Conditions:
Healthy
Chronic Disease
Eligibility:
All Genders
18-80 years
Brief Summary
The first reports of infections caused by SARS-CoV-2 were released from Wuhan, China in December 2019. From there, the infection quickly spread into a pandemic form. The clinical manifestation of the ...
Detailed Description
1. Title Serum prevalence of SARS-Cov-2 antibodies in pre-pandemic blood samples 2. Background The first reports of infections caused by SARS-CoV-2, a Beta Corona virus, single-stranded RNA, were rele...
Eligibility Criteria
Inclusion
- Both sexes
- Age \>18 years
- Signed informed consent for the donation / sample storage in the Biological Bank
Exclusion
- for healthy subjects: all those who have shown any symptoms, albeit mild, in the 28 days prior to the donation.
- for patients: who have not signed the informed consent for the conservation of their samples in the Biological Bank.
Key Trial Info
Start Date :
December 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2024
Estimated Enrollment :
3500 Patients enrolled
Trial Details
Trial ID
NCT04712448
Start Date
December 30 2020
End Date
December 30 2024
Last Update
April 10 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS San Raffaele
Rome, Italy, 00166